摘要
恶性淋巴瘤的靶向免疫检查点治疗通过阻断免疫抑制信号的传递,提高T细胞的抗肿瘤免疫反应,激活抗肿瘤的免疫效应,这种治疗方法可以获得持久的临床效应,成为恶性淋巴瘤治疗的新选择。现已发现的免疫检查点主要有程序性细胞死亡蛋白-1(Programmed death-1,PD-1)、细胞毒性T淋巴细胞相关抗原-4(Cytotoxic T lymphocyte associated-4,CTLA-4)和程序性死亡配体-1(Programmed death ligand 1,PD-L1)。本文简要综述了PD-1抑制剂、CTLA-4抑制剂及PD-Ll抑制剂在恶性淋巴瘤治疗中的研究进展,以及免疫的耐药机制和应对方法。
Targeted immune checkpoint therapy in malignant lymphoma, by blocking the transmission of immunosuppressive signals, could improve T cell anti-tumor immune response and activate anti-tumor immune effect. This treatment can achieve lasting clinical effects and has become a new choice of treatment for malignant lymphoma. The immune checkpoints found are mainly PD-1, CTLA-4 and PD-L1. This paper briefly reviews PD-1 inhibitors, CTLA-4 inhib- itors and PD-L1 inhibitors in the treatment of malignant lymphoma and the immune resistance mechanism and coping methods.
出处
《实用药物与临床》
CAS
2018年第1期104-108,共5页
Practical Pharmacy and Clinical Remedies
关键词
恶性淋巴瘤
免疫检查点抑制剂
免疫耐药
Malignant lymphoma
Immune checkpoint inhibitors
Immune resistance